Whole Inactivated Virus and Protein-Based COVID-19 Vaccines.

  title={Whole Inactivated Virus and Protein-Based COVID-19 Vaccines.},
  author={Peter Jay Hotez and Maria Elena Bottazzi},
  journal={Annual review of medicine},
The rapid development and deployment of mRNA and adenovirus-vectored vaccines against coronavirus disease 2019 (COVID-19) continue to astound the global scientific community, but these vaccine platforms and production approaches have still not achieved global COVID-19 vaccine equity. Immunizing the billions of people at risk for COVID-19 in the world's low- and middle-income countries (LMICs) still relies on the availability of vaccines produced and scaled through traditional technology… 
COVID-19 Vaccines: Current and Future Perspectives
The limits of vaccines developed against COVID-19 are discussed and possible innovative approaches are discussed, including strict storage at low temperatures for some vaccines and challenges regarding logistic problems.
mRNA Vaccines in the COVID-19 Pandemic and Beyond.
This review gives a detailed overview about the types of mRNA vaccines developed for SARS-CoV-2, discusses and compares preclinical and clinical data, gives a mechanistic overview about immune responses generated by mRNA vaccination, and speculates on the challenges and promising future of this emergent vaccine platform.
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
The primary efficacy endpoint was prevention of symptomatic SARS-CoV-2 infection with onset at least 7 days after the second injection and was triggered by the identification of [≥]160 virologically-confirmed cases, and tolerability and safety of CoVLP+AS03 were also determined.
Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine
The CoVLP+AS03 vaccine was effective in preventing Covid-19 caused by a spectrum of variants, with efficacy ranging from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.
Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models
Of the three tested vaccine regimens, the middle dose of the vaccine showed the best protective immune parameters and this vaccine with heterologous prime-boost vaccination method can be a good candidate to control the viral infection and its spread by stimulating central and mucosal immunity.
Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules
Viral proteins that contribute to COVID-19 infection and disease pathogenesis are reviewed according to the most recent research findings and the structure-function correlation of viral proteins provides a fundamental rationale for vaccine development and targeted therapy.
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles
The use of a SARS-CoV-2 dimeric recombinant RBD combined with Neisseria meningitidis outer membrane vesicles (OMVs), adsorbed on alum, as a promising COVID-19 vaccine candidate induces a potent and neutralizing immune response in laboratory animals, which is higher than that of the dimeric RBD alone adsorbing on alum.
Criteria for judging the immune markers of COVID‐19 disease vaccines
Anti‐spike immunoglobulin G and Ab to live SARS‐CoV‐2 may be good immune markers for VE assessment and neutralizing Ab toLive Sars‐Co V‐2 explained a fine relationship between antibody level and efficacy of different vaccine types.
The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants
It is demonstrated that the CoronaVac booster induced broad and potent adaptive immune responses that could be effective in controlling SARS-CoV-2 Delta and Omicron variants.
Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.
The finding that the loss of in vivo potency associated with heat-stressed RBD-J formulated with AH+CpG after one dose was abrogated by a booster highlights the importance of elucidating the key interrelationships between antigen-adjuvant interactions, storage stability, and in vivo performance to enable successful formulation development of stable and efficacious subunit vaccines.